EP Patent

EP2724742A1 — Conversion of nitrogen dioxide (no2) to nitric oxide (no)

Assigned to Vero Biotech Inc · Expires 2014-04-30 · 12y expired

What this patent protects

Inhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. A nitric oxide delivery system that converts nitrogen delivery system that converts nitrogen dioxide to nitric oxide employs a surface-active material, such as silica gel, …

USPTO Abstract

Inhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. A nitric oxide delivery system that converts nitrogen delivery system that converts nitrogen dioxide to nitric oxide employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid.

Drugs covered by this patent

Patent Metadata

Patent number
EP2724742A1
Jurisdiction
EP
Classification
—
Expires
2014-04-30
Drug substance claim
No
Drug product claim
No
Assignee
Vero Biotech Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.